替戈拉生单次和多次口服给药的安全性、耐受性、药代动力学与药效学:随机临床试验
本研究为Ⅰ期随机双盲安慰剂对照试验,在56例无幽门螺杆菌感染的健康男性中评估钾离子竞争性酸阻滞剂替戈拉生(CJ-12420)的安全性、耐受性、药代动力学和药效学。结果显示替戈拉生总体耐受良好,暴露量呈剂量比例增加,多次给药后第7天无血浆蓄积,并呈快速、剂量依赖性胃酸抑制。
要点
- 替戈拉生总体耐受良好,多数不良事件为轻度且无后遗症。
- 替戈拉生暴露量随剂量呈比例增加,多次给药第7天无血浆蓄积。
- 替戈拉生显示快速、剂量依赖性胃酸抑制。
核心结论
- 替戈拉生耐受良好,并显示快速且强效的胃酸抑制,支持其作为酸相关疾病治疗的进一步开发。
研究设计与样本
- Ⅰ期随机双盲安慰剂对照临床试验,纳入56例无幽门螺杆菌感染的健康男性受试者。
- 单次递增剂量研究:50、100、200和400 mg替戈拉生给予32例受试者。
- 多次递增剂量研究:100和200 mg替戈拉生每24小时给予各8例受试者,共7天。
- 药效学比较研究:40 mg埃索美拉唑每24小时给予8例受试者,共7天。
- 评估包括安全性、耐受性、24小时胃内pH监测的药效学及血浆和尿液中替戈拉生的药代动力学。
主要发现
- 替戈拉生总体耐受良好,研究中报告的大多数不良事件为轻度,且无需后遗症即缓解。
- 替戈拉生暴露量呈剂量比例增加。
- 替戈拉生多次给药后第7天血浆中未见蓄积。
- 药效学分析显示替戈拉生呈快速、剂量依赖性胃酸抑制。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tegoprazan (CJ-12420) is a potassium-competitive acid blocker (P-CAB) with therapeutic potential for gastro-oesophageal reflux disease (GERD) by reversibly suppressing gastric H+ /K+ -ATPase. AIMS: To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of tegoprazan METHODS: A phase I, randomised, double-blind and placebo-controlled clinical trial was conducted in 56 healthy male subjects without Helicobacter pylori infection. In the single ascending dose study, 50, 100, 200 and 400 mg tegoprazan were administered to 32 subjects. In the multiple ascending dose study, 100 and 200 mg tegoprazan were administered every 24 hours to each of the eight subjects for 7 days. In the comparative pharmacodynamics study, 40 mg esomeprazole was administered to eight subjects every 24 hours for 7 days. The assessment included safety, tolerability, pharmacodynamics through monitoring of 24-hour gastric pH and pharmacokinetics of tegoprazan in plasma and urine. RESULTS: Tegoprazan was generally well tolerated. Most adverse events reported in the study were mild in intensity and resolved without any sequelae. Exposure to tegoprazan increased in a dose-proportional manner. Multiple dosing with tegoprazan showed no accumulation in plasma on day 7. The pharmacodynamic analysis revealed that tegoprazan showed rapid, dose-dependent gastric acid suppression. CONCLUSIONS: Tegoprazan was well tolerated and showed rapid and potent gastric acid suppression. This supports the further development of tegoprazan as a treatment for acid-related disorders.
引用
- Han S, Choi HY, Kim YH, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019. PMID: 31437865. doi:10.1111/apt.15438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。